Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Similars in SciELO
Share
Horizonte sanitario
On-line version ISSN 2007-7459Print version ISSN 1665-3262
Abstract
LOPEZ-ESTEVES, Pablo et al. Cost-effectiveness in insulin treatment for type 2 diabetes mellitus control in Mexico. Horiz. sanitario [online]. 2022, vol.21, n.3, pp.433-441. Epub Sep 01, 2023. ISSN 2007-7459. https://doi.org/10.19136/hs.a21n3.4769.
Objective:
To identify the best cost-effective intervention for the treatment of type 2 diabetes mellitus, at the first level of care, when the patient requires the use of insulin, based on previous clinical analysis.
Materials and methods:
A cost-effectiveness analysis was carried out, from the provider perspective. The cost of three types of insulin as a control drug were obtained: glargine insulin, neutral protamine Hagedorn (NPH) insulin and lispro insulin/lispro protamine 25-75 IU. The effectiveness indicators were obtained from previous studies that analyzed the effect on glycated hemoglobin (HbA1c).
Results:
The intervention that presented the best cost-effective coefficient was the treatment with glargine insulin, with a value of 570, compared to 643.1 for the NPH insulin and 57 for the lispro/lispro protamine insulin.
Conclusions:
Glargine insulin is the treatment in patients who require insulins, without microvascular damage, that presents the best evidence to invest in, because of its cost and efficiency (analyzed through a cost- efficiency coefficient). These results may be considered in the Mexican context to improve drug’s acquisition and the treatment standards to treat type 2 diabetes mellitus.
Keywords : Type 2 diabetes; Cost-effectiveness; Insulin.